Allogene Therapeutics, Inc. Form 8-K Summary
Reporting date: April 18, 2023; filed April 20, 2023. This current report concerns a change in executive leadership under Item 5.02. It does not report quarterly or annual financial results.
Business Context and Reporting Period
Allogene Therapeutics, Inc. is a Delaware biotechnology company headquartered in South San Francisco, California. Its common stock trades on Nasdaq under the symbol ALLO.
Leadership Change
- Alison Moore notified the company on April 18, 2023, that she would resign as Chief Technical Officer effective April 28, 2023, to pursue other opportunities.
- On April 19, 2023, the Board appointed Tim Moore as Chief Technical Officer effective April 24, 2023.
- The filing states that Tim Moore is expected to provide a period of transitional consulting services, with terms to be agreed between him and the company.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating expenses, or other financial metrics.
Material Changes, Outlook, and Risks
The material disclosed change is the transition in the Chief Technical Officer position. The filing provides no guidance, business outlook, operational impact assessment, compensation details, contingency disclosure, or unusual financial items related to the transition.
Investor Verification Points
- Confirm the effective dates of Alison Moore’s resignation and Tim Moore’s appointment.
- Review subsequent filings for the terms and duration of any transitional consulting arrangement.
- Assess subsequent disclosures for any impact of the leadership transition on development programs, manufacturing, regulatory activities, or execution.
- Refer to the company’s periodic reports for financial results, cash runway, liquidity, debt, and other operating metrics not included in this 8-K.